**Core Concept:**
Gonadotropin-releasing hormone (GnRH) agonists are medications that mimic the action of natural GnRH, which is responsible for regulating the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. In the context of treating leiomyomas, GnRH agonists are used to suppress the growth of uterine fibroids by reducing estrogen and progesterone levels.

**Why the Correct Answer is Right:**
The correct answer, GnRH agonist, works by binding to GnRH receptors in the anterior pituitary gland, triggering a cascade of events that ultimately leads to a decrease in LH and FSH secretion. This suppression of pituitary gland hormones results in a secondary decrease in gonadal steroid hormones - estrogen and progesterone production in the ovaries. As a consequence, the growth of uterine fibroids is slowed down or even halted.

**Why Each Wrong Option is Incorrect:**
A. GnRH antagonist (Option A) works by blocking the action of endogenous GnRH, preventing the activation of pituitary receptors. This option is incorrect because it does not lead to a decrease in LH and FSH secretion, thus not affecting progesterone levels.
B. Selective progesterone receptor modulators (SPRMs) are medications that modulate progesterone receptors, not directly decrease progesterone production. Although they may have some effect on fibroids, they are not as effective as GnRH agonists in suppressing progesterone levels.
C. Gonadotropin-releasing hormone antagonists (Option C) work by blocking the action of exogenous GnRH, preventing the binding of GnRH to pituitary receptors. This option is incorrect because it does not lead to a decrease in LH and FSH secretion, not affecting progesterone levels.
D. Selective estrogen receptor modulators (SERMs) modulate estrogen receptors, but they do not directly decrease estrogen production. Although they may have some effect on fibroids, they are not as effective as GnRH agonists in suppressing estrogen and progesterone levels.

**Clinical Pearl:**
GnRH agonists are considered the gold standard in the treatment of uterine fibroids due to their direct impact on the pituitary gland, leading to a decrease in LH and FSH secretion, and consequently, a decline in estrogen and progesterone production. This results in a significant reduction of uterine fibroids.